AACR Stories
Boosting the Immune Response to Cancer: Decades of pioneering research led to a first-of-its-kind FDA approval for a new type of immunotherapy—tumor-infiltrating lymphocyte (TIL) therapy.
Learn More in AACR Stories
Boosting the Immune Response to Cancer: Decades of pioneering research led to a first-of-its-kind FDA approval for a new type of immunotherapy—tumor-infiltrating lymphocyte (TIL) therapy.
Learn More in AACR Stories
Cancer is not a single disease, but rather a collection of diseases all characterized by the uncontrolled proliferation of cells.
Learn MoreThe inaugural AACR Pediatric Cancer Progress Report highlights research-driven advances in the prevention, detection, and treatment of childhood cancers.
Read the ReportNearly 85,000 people in the United States were diagnosed with bladder cancer last year. Learn more about screening and treatment for this type of cancer.
Learn MoreAACR Project GENIE is a publicly accessible international cancer registry of real-world data assembled through data sharing between many of the leading cancer centers in the world.
Learn MoreLeading Discoveries magazine is online with articles on pioneering researchers, collaboration among blood cancer researchers, donors who are driving progress in cancer science, and more.
Read Leading DiscoveriesWhether honoring a special person or a special day, a donation to the American Association for Cancer Research has a lasting impact.
Donate NowAdvance registration is open for the AACR Annual Meeting 2026. Register by February 27 to receive discounted rates.
The AACR Pediatric Cancer Progress Report 2025 highlights the remarkable progress against childhood cancers driven by discoveries across the basic, translational, clinical, and population sciences.
Learn MoreThe AACR and its more than 58,000 members worldwide are advancing a scientifically bold agenda against the collection of diseases we call cancer.
Learn MoreThe AACR Cancer Progress Report 2025 highlights research-driven advances against the collection of often devastating diseases we call cancer.
Learn Morepercent decrease of the overall age-adjusted cancer death rate in the U.S. from 1991 to 2023
Learn Moretherapeutics were approved for new or expanded uses by the FDA from July 1, 2024, to June 30, 2025
Learn Moremillion cancer survivors in the U.S. are living with, through, and beyond their disease thanks to research
Learn MoreYour donation to the American Association for Cancer Research helps our more than 61,000 members worldwide drive progress against cancer.
Donate Now
